FDA Grants Fast Track Status to SAB Biotherapeutics Type 1 Diabetes Drug SAB-142
SAB Biotherapeutics, Inc. (SABS) received Fast Track designation from the U.S. Food and Drug Administration for SAB-142, an investigational immunotherapy candidate for individuals with new-onset Stage 3 type 1 diabetes. The designation is intended to facilitate clinical development and accelerate regulatory review for treatments targeting serious conditions with significant unmet needs.
SAB-142 is a fully human anti-thymocyte immunoglobulin that aims to modify disease progression by delaying or preventing advancement in newly diagnosed patients. Fast Track status allows the company to engage in more frequent communication with regulators throughout trial phases.
The drug candidate is currently being evaluated in a Phase 2b clinical trial called SAFEGUARD for patients within 100 days of diagnosis. Patient enrollment is scheduled to wrap up in the fourth quarter of 2026, with topline trial results expected in the second half of 2027. An additional Phase 3 study led by investigators is testing the candidate in patients diagnosed between 100 days and two years prior.
Key points
- The FDA granted Fast Track designation to SAB Biotherapeutics for its type 1 diabetes drug candidate SAB-142.
- Fast Track status provides expedited regulatory review and increased guidance from the FDA for therapies addressing unmet medical needs.
- SAB-142 is currently in a Phase 2b clinical trial, with study enrollment set to complete in the fourth quarter of 2026.
- Topline data from the Phase 2b trial is anticipated in the second half of 2027.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
What did the FDA grant to SAB Biotherapeutics?
The FDA granted Fast Track designation to SAB-142, an immunotherapy candidate for treating newly diagnosed Stage 3 type 1 diabetes.
When will SAB Biotherapeutics release Phase 2b trial data for SAB-142?
Enrollment for the Phase 2b study is expected to complete in the fourth quarter of 2026, with topline trial results anticipated in the second half of 2027.
What does FDA Fast Track designation mean for SAB-142?
Fast Track designation is designed to facilitate development and speed up regulatory review for therapies addressing serious conditions with unmet medical needs.